416 related articles for article (PubMed ID: 10077975)
21. Selegiline and the prophylaxis of Parkinson's disease.
Sandler M; Willoughby J; Glover V; Gibb C
J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
[TBL] [Abstract][Full Text] [Related]
22. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Vaglini F; Pardini C; Viaggi C; Bartoli C; Dinucci D; Corsini GU
J Neurochem; 2004 Oct; 91(2):285-98. PubMed ID: 15447662
[TBL] [Abstract][Full Text] [Related]
23. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Hirsch E; Graybiel AM; Agid YA
Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease.
Shen XM; Xia B; Wrona MZ; Dryhurst G
Chem Res Toxicol; 1996; 9(7):1117-26. PubMed ID: 8902266
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
27. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
Nagel F; Bähr M; Dietz GP
Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215
[TBL] [Abstract][Full Text] [Related]
29. A cell-permeable peptide inhibitor TAT-JBD reduces the MPP+-induced caspase-9 activation but does not prevent the dopaminergic degeneration in substantia nigra of rats.
Pain S; Barrier L; Deguil J; Milin S; Piriou A; Fauconneau B; Page G
Toxicology; 2008 Jan; 243(1-2):124-37. PubMed ID: 18037221
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
[TBL] [Abstract][Full Text] [Related]
31. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease.
Geng X; Tian X; Tu P; Pu X
Eur J Pharmacol; 2007 Jun; 564(1-3):66-74. PubMed ID: 17359968
[TBL] [Abstract][Full Text] [Related]
34. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Hare DJ; Adlard PA; Doble PA; Finkelstein DI
Metallomics; 2013 Feb; 5(2):91-109. PubMed ID: 23322189
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
36. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
37. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Belzunegui S; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neuropathol Exp Neurol; 2009 Jan; 68(1):26-36. PubMed ID: 19104449
[TBL] [Abstract][Full Text] [Related]
38. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A
Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291
[TBL] [Abstract][Full Text] [Related]
39. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
40. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
Kurkowska-Jastrzebska I; Bałkowiec-Iskra E; Ciesielska A; Joniec I; Cudna A; Zaremba MM; Członkowski A; Członkowska A
Int Immunopharmacol; 2009 Jun; 9(6):781-91. PubMed ID: 19286483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
